FDA Approves CIBINQO — U.S. Pharmaceuticals

New York, January 14, 2022 – U.S. Pharmaceuticals announced today the FDA approval of CIBINQO (abrocitinib), a novel oral therapy for chronic urticaria, marking a significant commercial opportunity for the company to penetrate the growing market for chronic itch treatments. The approval of this fast-acting IL-4 receptor alpha antagonist positions U.S. Pharmaceuticals to capitalize on increasing patient demand while potentially altering the competitive landscape through its favorable pharmacokinetic profile.